7/10/2026

Adalimumab-ryvk Subcutaneous Injection

Products Affected - Description

- Simlandi subcutaneous solution for injection, Teva, 20 mg/0.2 mL, prefilled syringe, 2 count, NDC 51759-0386-22
- Simlandi subcutaneous solution for injection, Teva, 40 mg/0.4 mL, auto-injector, 1 count, NDC 51759-0402-17
- Simlandi subcutaneous solution for injection, Teva, 40 mg/0.4 mL, auto-injector, 2 count, NDC 51759-0402-02
- Simlandi subcutaneous solution for injection, Teva, 40 mg/0.4 mL, prefilled syringe, 2 count, NDC 51759-0412-22
- Simlandi subcutaneous solution for injection, Teva, 80 mg/0.8 mL, auto-injector, 1 count, NDC 51759-0274-17

Reason for the Shortage

- Teva did not provide a reason for the shortage.

Available Products

- Adalimumab-ryvk subcutaneous solution for injection, Teva, 40 mg/0.4 mL, auto-injector, 2 count, NDC 51759-0310-59
- Adalimumab-ryvk subcutaneous solution for injection, Teva, 40 mg/0.4 mL, auto-injector, 2 count, NDC 51759-0360-02
- Adalimumab-ryvk subcutaneous solution for injection, Teva, 80 mg/0.8 mL, auto-injector, 1 count, NDC 51759-0311-58
- Adalimumab-ryvk subcutaneous solution for injection, Teva, 80 mg/0.8 mL, auto-injector, 1 count, NDC 51759-0361-17

Estimated Resupply Dates

- Teva has all brand name Simlandi presentations on allocation.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.